These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29174475)

  • 1. Temporal trends in the premorbid use of preventive treatments in patients with acute ischemic cerebrovascular events and a history of vascular disease: The Dijon Stroke Registry (1985-2010).
    Khoumri C; Bailly H; Delpont B; Daubail B; Blanc C; Chazalon C; Durier J; Hervieu-Bègue M; Osseby GV; Rouaud O; Giroud M; Vergely C; Béjot Y
    Presse Med; 2017 Dec; 46(12 Pt 1):e259-e267. PubMed ID: 29174475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary prevention in patients with vascular disease. A population based study on the underuse of recommended medications.
    Béjot Y; Zeller M; Lorgis L; Troisgros O; Aboa-Eboulé C; Osseby GV; Giroud M; Cottin Y
    J Neurol Neurosurg Psychiatry; 2013 Mar; 84(3):348-53. PubMed ID: 23152636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid transfer to high-density lipoproteins in coronary artery disease patients with and without previous cerebrovascular ischemic events.
    Barbosa CJDG; Maranhão RC; Barreiros RS; Freitas FR; Franci A; Strunz CMC; Arantes FBB; Tavoni TM; Ramires JAF; Kalil Filho R; Nicolau JC
    Clin Cardiol; 2019 Nov; 42(11):1100-1105. PubMed ID: 31489679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal combination treatment and vascular outcomes in recent ischemic stroke patients by premorbid risk level.
    Park JH; Ovbiagele B
    J Neurol Sci; 2015 Aug; 355(1-2):90-3. PubMed ID: 26044963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA.
    Ovbiagele B; Hills NK; Saver JL; Johnston SC
    Neurology; 2006 Feb; 66(3):313-8. PubMed ID: 16476928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals?
    Saposnik G; Goodman SG; Leiter LA; Yan RT; Fitchett DH; Bayer NH; Casanova A; Langer A; Yan AT; ; ;
    Stroke; 2009 Apr; 40(4):1417-24. PubMed ID: 19213947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics and prevention among patients with stroke: a study of 36,844 patients hospitalized in France].
    Tuppin P; Moysan V; de Peretti C; Schnitzler A; Fery-Lemonnier E; Woimant F
    Rev Neurol (Paris); 2013 Feb; 169(2):126-35. PubMed ID: 22749335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis.
    Ruigómez A; Johansson S; Wallander MA; Edvardsson N; García Rodríguez LA
    Int J Cardiol; 2009 Aug; 136(2):186-92. PubMed ID: 18625526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes.
    Bhatt DL; Peterson ED; Harrington RA; Ou FS; Cannon CP; Gibson CM; Kleiman NS; Brindis RG; Peacock WF; Brener SJ; Menon V; Smith SC; Pollack CV; Gibler WB; Ohman EM; Roe MT;
    Eur Heart J; 2009 May; 30(10):1195-202. PubMed ID: 19339264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary medical prevention after primary vascular surgery between 1996 and 2006: a shift towards more evidence-based treatment.
    Høgh A; Lindholt JS; Nielsen H; Jensen LP; Johnsen SP
    Eur J Prev Cardiol; 2013 Oct; 20(5):763-70. PubMed ID: 22637739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary Prevention Three and Six Years after Stroke Using the French National Insurance Healthcare System Database.
    Mechtouff L; Haesebaert J; Viprey M; Tainturier V; Termoz A; Porthault-Chatard S; David JS; Derex L; Nighoghossian N; Schott AM
    Eur Neurol; 2018; 79(5-6):272-280. PubMed ID: 29758555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Experience With Preventive Medication and Personal Risk Attitude in Non-Attendance at Triple Vascular Screening.
    Hansen TB; Lindholt JS; Søgaard R
    Eur J Vasc Endovasc Surg; 2018 Aug; 56(2):282-290. PubMed ID: 29891436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial.
    Jeng JS; Sun Y; Lee JT; Lin RT; Chen CH; Po HL; Lin HJ; Liu CH; Sun MH; Sun MC; Chern CM; Lien LM; Chiu HC; Hu HH; Chiou HY; Chen ST; Ma H; Hsu CY;
    Int J Stroke; 2015 Jan; 10(1):123-7. PubMed ID: 25394855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in the incidence of transient ischemic attacks, premorbid risk factors and the use of preventive treatments in the population of Dijon, France from 1985 to 2004.
    Bejot Y; Rouaud O; Benatru I; Durier J; Caillier M; Couvreur G; Fromont A; Falvo N; Osseby GV; Cottin Y; Zeller M; Millerot E; Marie C; Moreau T; Giroud M
    Cerebrovasc Dis; 2007; 23(2-3):126-31. PubMed ID: 17124393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The disparity in long-term survival after a first stroke in patients with and without diabetes persists: the Northern Sweden MONICA study.
    Eriksson M; Carlberg B; Eliasson M
    Cerebrovasc Dis; 2012; 34(2):153-60. PubMed ID: 22907276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparities between prescribing of secondary prevention therapies for stroke and coronary artery disease in general practice.
    Heeley E; Anderson C; Patel A; Cass A; Peiris D; Weekes A; Chalmers J
    Int J Stroke; 2012 Dec; 7(8):649-54. PubMed ID: 21978147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains.
    Subherwal S; Patel MR; Kober L; Peterson ED; Jones WS; Gislason GH; Berger J; Torp-Pedersen C; Fosbol EL
    Circulation; 2012 Sep; 126(11):1345-54. PubMed ID: 22874581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization.
    Sigvant B; Kragsterman B; Falkenberg M; Hasvold P; Johansson S; Thuresson M; Nordanstig J
    J Vasc Surg; 2016 Oct; 64(4):1009-1017.e3. PubMed ID: 27209402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary medical prevention and clinical outcome in coronary artery disease patients with a history of non-coronary vascular intervention: A report from the CORONOR investigators.
    Delsart P; Lemesle G; Lamblin N; Tricot O; Meurice T; Mycinski C; Elkohen M; Chmait A; Haulon S; Bauters C
    Eur J Prev Cardiol; 2015 Jul; 22(7):864-71. PubMed ID: 24914029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.